血常规参数与妇科恶性肿瘤预后关系的研究进展

摘要/Abstract

中图分类号:

R737.3

戴允楠, 殷玉明, 李青山. 血常规参数与妇科恶性肿瘤预后关系的研究进展[J]. 承德医学院学报, 2020, 37(6): 512-515.

[1] Orozco-Morales M, Soca-Chafre G, Barrios-Bernal P, et al.Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer[J]. Mediators Inflamm, 2016, 2016: 1-11.
[2] Balkwill F, Mantovani A.Inflammation and cancer: back to Virchow?[J]. Lancet, 2001, 357(9255): 539-545.
[3] Abu-Shawer O, Abu-Shawer M, Hirmas N, et al.Hematologic markers of distant metastases and poor prognosis in gynecological cancers[J]. BMC Cancer, 2019, 19(1): 141.
[4] Rassouli A, Saliba J, Castano R, et al.Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma: Inflammatory Markers in Head and Neck Malignancies[J]. Head Neck, 2015, 37(1): 103-110.
[5] Fang L, Xu X, Ji Y, et al.The Prognostic Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Resected Patients with Pancreatic Adenocarcinoma[J]. World J Surg, 2018, 42(11): 3736-3745.
[6] Azab B, Shah N, Radbel J, et al.Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients[J]. Med Oncol, 2013, 30(1): 432.
[7] Pirozzolo G, Gisbertz SS, Castoro C, et al.Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis[J]. J Thorac Dis, 2019, 11(7): 3136-3145.
[8] Cummings M, Merone L, Keeble C, et al.Preoperative neutrophil: lymphocyte and platelet: lymphocyte ratios predict endometrial cancer survival[J]. Br J Cancer, 2015, 113(2): 311-320.
[9] Haruma T, Nakamura K, Nishida T, et al.Pre-treatment Neutrophil to Lymphocyte Ratio Is a Predictor of Prognosis in Endometrial Cancer[J]. Anticancer Res, 2015, 35(1): 337-343.
[10] Holub K, Busato F, Gouy S, et al.Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External Radiotherapy[J]. J Clin Med, 2020, 9(5): 1441.
[11] Ding L, Ding Y, Mao X, et al.Retrospective study of the prognostic significance of neutrophil, to, lymphocyte ratio for postsurgical outcomes of patients with endometrial carcinoma[J]. Int J Gynaecol Obstet, 2017, 138(3): 311-319.
[12] Ni L, Tao J, Xu J, et al.Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta- analysis[J]. Arch Gynecol Obstet, 2020, 301(1): 251-261.
[13] Temur I, Gulec UK, Paydas S, et al.Prognostic value of pre-operative neutrophil/ lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 226: 25-29.
[14] Li J, Lin J, Luo Y, et al.Multivariate Analysis of Prognostic Biomarkers in Surgically Treated Endometrial Cancer[J]. PLoS One, 2015, 10(6), 1-11.
[15] Cömert GK, Türkmen O, Kar İ, et al.Independent predictors of survival in endometrium cancer:platelet-to-lymphocyte ratio and platelet/neutrophil/monocyte-to-lymphocyte ratio[J]. J Turk Ger Gynecol Assoc, 2018, 19(2): 78-86.
[16] Kurtoglu E, Kokcu A, Celik H, et al.Platelet Indices May be Useful in Discrimination of Benign and Malign Endometrial Lesions, and Early and Advanced Stage Endometrial Cancer[J]. Asian Pac J Cancer Prev, 2015, 16(13): 5397-5400.
[17] Eo WK, Kwon S, Koh SB, et al.The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Endometrial Cancer[J]. J Cancer, 2016, 7(5): 538-545.
[18] Cong R, Kong F, Ma J, et al.Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer[J]. BMC Cancer, 2020, 20(1): 464.
[19] Kwon BS, Lee HJ, Yang J, et al.Prognostic value of preoperative lymphocyte-monocyte ratio in elderly patients with advanced epithelial ovarian cancer[J]. Obstet Gynecol Sci, 2017, 60(6): 558-564.
[20] Kwon BS, Jeong DH, Byun JM, et al.Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma[J]. J Cancer, 2018, 9(7): 1127-1134.
[21] Eo WK, Chang HJ, Kwon SH, et al.The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer[J]. J Cancer, 2016, 7(3): 289-296.
[22] Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al.Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer[J]. J Gynecol Oncol, 2012, 23(4): 265-273.
[23] Miao Y, Yan Q, Li S, et al.Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy[J]. Cancer Biomark, 2016, 17(1): 33-40.
[24] Yang Z, Gu JH, Guo CS, et al.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies[J]. Oncotarget, 2017,8(28): 46414-46424.
[25] Zhu Y, Zhou S, Liu Y, et al.Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review[J]. BMC Cancer, 2018, 18(1): 443.
[26] Marchetti C, Romito A, Musella A, et al.Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role?[J]. Int J Gynecol Cancer, 2018, 28(5): 939-944.
[27] Yildirim MA, Seckin KD, Togrul C, et al.Roles of Neutrophil/Lymphocyte and Platelet/ Lymphocyte Ratios in the Early Diagnosis of Malignant Ovarian Masses[J]. Asian Pac J Cancer Prev, 2014, 15(16): 6881-6885.
[28] Topcu HO, Guzel AI, Ozer I, et al.Comparison of Neutrophil/Lymphocyte and Platelet/ Lymphocyte Ratios for Predicting Malignant Potential of Suspicious Ovarian Masses in Gynecology Practice[J]. Asian Pac J Cancer Prev, 2014, 15(15): 6239-6241.
[29] Zhu M, Feng M, He F, et al.Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer[J]. Clin Chim Acta, 2018, 483: 296-302.
[30] Kozasa K, Mabuchi S, Komura N, et al.Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review[J]. Oncotarget, 2017, 8(33): 55394-55404.
[31] Zhang Y, WANG L, LIU Y, et al.Preoperative Neutrophil-Lymphocyte Ratio Before Platelet -Lymphocyte Ratio Predicts Clinical Outcome in Patients With Cervical Cancer Treated With Initial Radical Surgery[J]. Int J Gynecol Cancer, 2014, 24(7): 1319-1325.
[32] Nakamura K, Nakayama K, Tatsumi N, et al.Prognostic significance of pre-treatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in non-surgically treated uterine cervical carcinoma[J]. Mol Clin Oncol, 2018, 9(2): 138-144.
[33] Jonska-Gmyrek J, Gmyrek L, Zolciak-Siwinska A, et al.Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients[J]. Cancer Manag Res, 2018, 10: 6029-6038.
[34] Wang D, Wu M, Feng FZ, et al.Pretreatment neutrophil-to-lymphocyte and platelet-to- lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy[J]. Chin Med J (Engl), 2013, 126(8): 1464-1468.
[35] Kose M, Celik F, Kose SK, et al.Could the Platelet-to-Lymphocyte Ratio be a Novel Marker for Predicting Invasiveness of Cervical Pathologies?[J]. Asian Pac J Cancer Prev, 2015, 16(3): 923-926.
[36] Prabawa IPY, Bhargah A, Liwang F, et al.Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer[J]. Asian Pac J Cancer Prev, 2019, 20(3): 863-868.
[37] Mizunuma M, Yokoyama Y, Futagami M, et al.The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J]. Int J Clin Oncol, 2015, 20(5): 989-996
[38] Ethier JL, Desautels DN, Templeton AJ, et al.Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta- analysis[J]. Gynecol Oncol, 2017, 145(3): 584-594.

血常规参数与妇科恶性肿瘤预后关系的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	严汀华, 谢雪华, 江金华, 吴炜. NLR在乙肝相关慢加急性肝衰竭诊断及预后预测价值[J]. 承德医学院学报, 2021, 38(5): 379-382.
[2]	李雪峰, 王清芳, 冯玉凤. Lp-PLA2、Annexin A2与溶栓后急性缺血性脑卒中患者预后的相关性[J]. 承德医学院学报, 2021, 38(4): 301-305.
[3]	曾宪任. 优化急诊护理流程对急性心肌梗死患者救治效果的分析[J]. 承德医学院学报, 2021, 38(4): 317-319.
[4]	王丹丹, 巨士文. 子宫内膜异位症患者VEGF、MMP-9、tPA水平与预后关系分析[J]. 承德医学院学报, 2021, 38(3): 191-194.
[5]	王丽娟, 刘燕. miR-708在儿童急性淋巴细胞白血病中的诊断及预后[J]. 承德医学院学报, 2021, 38(1): 1-5.
[6]	卓艳霞, 孙明昌, 张永卓. 儿童急性淋巴细胞白血病中miR-326的表达及临床意义[J]. 承德医学院学报, 2021, 38(1): 9-12.
[7]	何孝敏. 原发性肝癌患者TSGF、GP73水平与预后关系的研究[J]. 承德医学院学报, 2020, 37(5): 374-377.
[8]	张莉. 急性ST段抬高型心肌梗死患者可溶性致癌抑制因子2水平与预后的相关性[J]. 承德医学院学报, 2020, 37(4): 296-298.
[9]	邝静. 俯卧位通气护理对严重创伤后ARDS患者预后的影响[J]. 承德医学院学报, 2020, 37(1): 52-53.
[10]	张燕, 斯琴高娃. 人乳头瘤病毒及疫苗的研究进展[J]. 承德医学院学报, 2019, 36(6): 515-519.
[11]	盛欢欢. 彩超引导下射频消融术治疗甲状腺良性结节的效果及预后观察[J]. 承德医学院学报, 2019, 36(5): 371-374.
[12]	薛晶雯, 王又君, 郭静, 张金洋, 吕喜英. 预后营养指数评估小细胞肺癌患者预后的临床价值[J]. 承德医学院学报, 2019, 36(5): 393-397.
[13]	乔方. 降钙素原、血小板计数评估多发性创伤患者预后的价值[J]. 承德医学院学报, 2018, 35(6): 478-480.
[14]	王浩, 斯琴高娃, 武敏. 宫颈癌中SCC-Ag与miR-21表达的联系及临床联合检测研究进展[J]. 承德医学院学报, 2018, 35(5): 421-425.
[15]	张云鹏, 陈肖, 李静, 申晓平, 魏依兰, 窦志杰. H型高血压对急性脑梗死患者静脉溶栓治疗预后的影响[J]. 承德医学院学报, 2018, 35(4): 285-288.